{"date":"2025-12-19","count":29,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4745-2025-12-19-2202-oxtxom","company_id":"4745","company":"合富-KY","market":"上櫃","industry":"生技醫療","date":"2025-12-19","time":"22:02:19","subject":"(補充114/10/9公告) 子公司合富(中國)醫療科技股份有限公司，擬投資明基醫院集團股份有限公司股權案","clause":"第20款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：合富-KY（4745），2025-12-19 22:02，「(補充114/10/9公告) 子公司合富(中國)醫療科技股份有限公司，擬投資明基醫院集團股份有限公司股權案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4745-2025-12-19-2135-z3r9at","company_id":"4745","company":"合富-KY","market":"上櫃","industry":"生技醫療","date":"2025-12-19","time":"21:35:31","subject":"代重要子公司合富（中國）醫療科技股份有限公司公告2025年第二次股東臨時會決議事項","clause":"第18款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：合富-KY（4745），2025-12-19 21:35，「代重要子公司合富（中國）醫療科技股份有限公司公告2025年第二次股東臨時會決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-8403-2025-12-19-2048-15820f8","company_id":"8403","company":"盛弘","market":"上櫃","industry":"生技醫療","date":"2025-12-19","time":"20:48:29","subject":"本公司董事會通過對關係人捐贈事宜","clause":"第43款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：盛弘（8403），2025-12-19 20:48，「本公司董事會通過對關係人捐贈事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7773-2025-12-19-1939-kcxezo","company_id":"7773","company":"富禾生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-19","time":"19:39:55","subject":"本公司利用自體培養之EB病毒專一性毒殺T細胞對鼻咽癌病患所進行之免疫療法「EBaT8」第一跨二a期臨床試驗申請，接獲臺灣衛生福利部來函通知不予受理，並請重新擬定計畫提出申請。","clause":"第44款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：富禾生醫（7773），2025-12-19 19:39，「本公司利用自體培養之EB病毒專一性毒殺T細胞對鼻咽癌病患所進行之免疫療法「EBaT8」第一跨二a期臨床試驗申請，接獲臺灣」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6589-2025-12-19-1848-p1h1y8","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2025-12-19","time":"18:48:34","subject":"本公司註銷限制員工權利新股減資變更登記完成","clause":"第36款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2025-12-19 18:48，「本公司註銷限制員工權利新股減資變更登記完成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6748-2025-12-19-1819-19q8zho","company_id":"6748","company":"亞果生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-19","time":"18:19:49","subject":"公告本公司114年度現金增資全體董事放棄認購股數達得認購股數二分之一以上，並洽特定人認購事宜","clause":"第37款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：亞果生醫（6748），2025-12-19 18:19，「公告本公司114年度現金增資全體董事放棄認購股數達得認購股數二分之一以上，並洽特定人認購事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7427-2025-12-19-1809-omze3o","company_id":"7427","company":"華上生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-19","time":"18:09:25","subject":"公告華上生醫自主開發新一代表觀免疫調控抗癌候選新藥GNTbm-38，取得俄羅斯發明專利","clause":"第44款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：華上生醫（7427），2025-12-19 18:09，「公告華上生醫自主開發新一代表觀免疫調控抗癌候選新藥GNTbm-38，取得俄羅斯發明專利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6677-2025-12-19-1803-p67uuk","company_id":"6677","company":"瑩碩生技","market":"興櫃","industry":"生技醫療","date":"2025-12-19","time":"18:03:24","subject":"公告本公司內部稽核主管異動","clause":"第11款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：瑩碩生技（6677），2025-12-19 18:03，「公告本公司內部稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2025-12-19-1801-1a8bkut","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2025-12-19","time":"18:01:36","subject":"補充說明114/07/31董事會決議發行114年國內第一次有擔保轉換公司債相關事宜","clause":"第11款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2025-12-19 18:01，「補充說明114/07/31董事會決議發行114年國內第一次有擔保轉換公司債相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4743-2025-12-19-1750-pdg1i0","company_id":"4743","company":"合一","market":"上櫃","industry":"生技醫療","date":"2025-12-19","time":"17:50:43","subject":"公告本公司Bonvadis外用乳膏，取得印度醫藥品監管機構(CDSCO核准完全傷口適應症之醫材上市許可","clause":"第10款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：合一（4743），2025-12-19 17:50，「公告本公司Bonvadis外用乳膏，取得印度醫藥品監管機構(CDSCO核准完全傷口適應症之醫材上市許可」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6666-2025-12-19-1738-bmu4ef","company_id":"6666","company":"羅麗芬-KY","market":"上市","industry":"生技醫療","date":"2025-12-19","time":"17:38:56","subject":"本公司受邀參加元富證券所舉辦之法說會","clause":"第12款","fact_date":"2025-12-23","cite_as":"公開資訊觀測站重大訊息：羅麗芬-KY（6666），2025-12-19 17:38，「本公司受邀參加元富證券所舉辦之法說會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6879-2025-12-19-1729-1bkm0mx","company_id":"6879","company":"大江基因","market":"興櫃","industry":"生技醫療","date":"2025-12-19","time":"17:29:09","subject":"公告本公司代理發言人異動","clause":"第11款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：大江基因（6879），2025-12-19 17:29，「公告本公司代理發言人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6879-2025-12-19-1727-wr0tu2","company_id":"6879","company":"大江基因","market":"興櫃","industry":"生技醫療","date":"2025-12-19","time":"17:27:32","subject":"公告本公司總經理異動","clause":"第6款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：大江基因（6879），2025-12-19 17:27，「公告本公司總經理異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6748-2025-12-19-1704-1sm3lw","company_id":"6748","company":"亞果生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-19","time":"17:04:13","subject":"公告本公司114年現金增資股款催繳事宜","clause":"第44款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：亞果生醫（6748），2025-12-19 17:04，「公告本公司114年現金增資股款催繳事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6939-2025-12-19-1703-5rax5d","company_id":"6939","company":"啟弘生技","market":"興櫃","industry":"生技醫療","date":"2025-12-19","time":"17:03:49","subject":"公告本公司董事會決議員工認股權憑證轉換普通股增資基準日","clause":"第9款","fact_date":"2025-12-15","cite_as":"公開資訊觀測站重大訊息：啟弘生技（6939），2025-12-19 17:03，「公告本公司董事會決議員工認股權憑證轉換普通股增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6645-2025-12-19-1700-1s7xzm3","company_id":"6645","company":"金萬林-創","market":"上市","industry":"生技醫療","date":"2025-12-19","time":"17:00:43","subject":"公告本公司向關係人取得使用權資產","clause":"第20款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：金萬林-創（6645），2025-12-19 17:00，「公告本公司向關係人取得使用權資產」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6645-2025-12-19-1659-mxqyj5","company_id":"6645","company":"金萬林-創","market":"上市","industry":"生技醫療","date":"2025-12-19","time":"16:59:56","subject":"本公司修訂「國內第一次有擔保轉換公司債發行及轉換辦法」之債權人公告","clause":"第51款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：金萬林-創（6645），2025-12-19 16:59，「本公司修訂「國內第一次有擔保轉換公司債發行及轉換辦法」之債權人公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6645-2025-12-19-1658-1krphe5","company_id":"6645","company":"金萬林-創","market":"上市","industry":"生技醫療","date":"2025-12-19","time":"16:58:25","subject":"公告本公司董事會通過修訂國內第一次有擔保轉換公司債發行及轉換辦法","clause":"第11款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：金萬林-創（6645），2025-12-19 16:58，「公告本公司董事會通過修訂國內第一次有擔保轉換公司債發行及轉換辦法」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2025-12-19-1654-1kekmir","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2025-12-19","time":"16:54:01","subject":"公告本公司辦理股票初次上櫃前現金增資收足股款暨現金增資基準日","clause":"第44款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2025-12-19 16:54，「公告本公司辦理股票初次上櫃前現金增資收足股款暨現金增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7607-2025-12-19-1644-hhuctq","company_id":"7607","company":"通用幹細胞*","market":"興櫃","industry":"生技醫療","date":"2025-12-19","time":"16:44:51","subject":"公告本公司「經修飾的巨噬細胞、其組成物及其用途」取得美國發明專利","clause":"第44款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：通用幹細胞*（7607），2025-12-19 16:44，「公告本公司「經修飾的巨噬細胞、其組成物及其用途」取得美國發明專利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4747-2025-12-19-1607-iv6i04","company_id":"4747","company":"強生*","market":"上櫃","industry":"生技醫療","date":"2025-12-19","time":"16:07:10","subject":"公告本公司受邀統一綜合證券舉辦聯合實體暨線上法人說明會","clause":"第12款","fact_date":"2025-12-23","cite_as":"公開資訊觀測站重大訊息：強生*（4747），2025-12-19 16:07，「公告本公司受邀統一綜合證券舉辦聯合實體暨線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6461-2025-12-19-1603-10jca0t","company_id":"6461","company":"益得","market":"上櫃","industry":"生技醫療","date":"2025-12-19","time":"16:03:19","subject":"本公司受邀參加凱基證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-12-30","cite_as":"公開資訊觀測站重大訊息：益得（6461），2025-12-19 16:03，「本公司受邀參加凱基證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6796-2025-12-19-1601-1lhxtkt","company_id":"6796","company":"晉弘","market":"上市","industry":"生技醫療","date":"2025-12-19","time":"16:01:53","subject":"公告本公司114年現金增資認股基準日等相關事宜(補充公告每股發行價格)","clause":"第11款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：晉弘（6796），2025-12-19 16:01，「公告本公司114年現金增資認股基準日等相關事宜(補充公告每股發行價格)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7607-2025-12-19-1552-1693vso","company_id":"7607","company":"通用幹細胞*","market":"興櫃","industry":"生技醫療","date":"2025-12-19","time":"15:52:57","subject":"公告本公司董事會決議召開115年第一次股東臨時會","clause":"第32款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：通用幹細胞*（7607），2025-12-19 15:52，「公告本公司董事會決議召開115年第一次股東臨時會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2025-12-19-1432-1goopfz","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2025-12-19","time":"14:32:22","subject":"本公司董事會通過與TegMine Therapeutics, Inc.簽訂受其委託開發之醣蛋白單抗ADC商業授權合約","clause":"第10款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2025-12-19 14:32，「本公司董事會通過與TegMine Therapeutics, Inc.簽訂受其委託開發之醣蛋白單抗ADC商業授權合約」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2025-12-19-1431-kcrxyx","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2025-12-19","time":"14:31:42","subject":"本公司董事會決議解除經理人競業禁止之限制","clause":"第21款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2025-12-19 14:31，「本公司董事會決議解除經理人競業禁止之限制」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2025-12-19-1430-1cnol71","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2025-12-19","time":"14:30:53","subject":"依「公開發行公司資金貸與及背書保證處理準則」第22條第一項第三款規定公告","clause":"第23款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2025-12-19 14:30，「依「公開發行公司資金貸與及背書保證處理準則」第22條第一項第三款規定公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1799-2025-12-19-1358-87f7k2","company_id":"1799","company":"易威","market":"上櫃","industry":"生技醫療","date":"2025-12-19","time":"13:58:13","subject":"本公司受邀參加德信證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：易威（1799），2025-12-19 13:58，「本公司受邀參加德信證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6864-2025-12-19-0855-3cbqxc","company_id":"6864","company":"元樟生技","market":"興櫃","industry":"生技醫療","date":"2025-12-19","time":"08:55:20","subject":"本公司與越南Tien Nong Industrial & AgriculturalJoint Stock Company簽署合作備忘錄","clause":"第8款","fact_date":"2025-12-19","cite_as":"公開資訊觀測站重大訊息：元樟生技（6864），2025-12-19 08:55，「本公司與越南Tien Nong Industrial & AgriculturalJoint Stock Company」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}